Trial Profile

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Renal Impairment and Volume Overload Despite the Standard Treatment with Conventional Diuretics

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolvaptan (Primary) ; Diuretics; Furosemide
Indications Heart failure; Renal impairment
Focus Therapeutic Use
Acronyms K-STAR

Most Recent Events

02 Sep 2015 Primary endpoint has been met. (Urinary output), according to an abstract presented at the the ESC Congress 2015: Annual Congress of the European Society of Cardiology
02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
03 Dec 2012 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com